Repligen jumps on strong annual forecast and quarterly results beat

Repligen

20/02/2025 15:18

** Life sciences firm Repligen's  RGEN.O  shares rise 8.9%
to $164.1
    ** Stock set for best day since July 2024 if gains hold
    ** Co forecasts 2025 annual revenue in the range of $685 mln
to $710 mln, above Wall Street estimates of $693.48 mln as per
data compiled by LSEG 
    ** Co expects to earn between $1.67/share and $1.76/share
for 2025 vs analysts' est of 1.67/share 
    ** Co reports Q4 profit of 44 cents/share vs analysts' est
of 41 cents/share  
    ** Co posts Q4 revenue of $168 mln, beating analysts'
estimates of $167.7 mln driven by more orders in its filtration
and analytics unit  
    ** Stock has fallen 22% in the last 12 months 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))